Head to Head Survey: Mosaic ImmunoEngineering (OTCMKTS:CPMV) & XBiotech (NASDAQ:XBIT)

Mosaic ImmunoEngineering (OTCMKTS:CPMV) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Mosaic ImmunoEngineering and XBiotech”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mosaic ImmunoEngineering	N/A	N/A	-$690,000.00	($0.09)	-7.49
XBiotech	N/A	N/A	-$45.54 million	($1.32)	-1.80

Mosaic ImmunoEngineering is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mosaic ImmunoEngineering and XBiotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mosaic ImmunoEngineering	N/A	N/A	-1,908.81%
XBiotech	N/A	-26.10%	-25.06%

Insider and Institutional Ownership

55.7% of XBiotech shares are owned by institutional investors. 81.0% of Mosaic ImmunoEngineering shares are owned by company insiders. Comparatively, 30.8% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Mosaic ImmunoEngineering has a beta of -0.84, meaning that its share price is 184% less volatile than the S&P 500. Comparatively, XBiotech has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Mosaic ImmunoEngineering and XBiotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mosaic ImmunoEngineering	0	0	0	0	0.00
XBiotech	1	0	0	0	1.00

Summary

XBiotech beats Mosaic ImmunoEngineering on 5 of the 9 factors compared between the two stocks.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

About XBiotech

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.